Company profile
Organigram Global Inc.
NASDAQ: OGI · Healthcare · Drug Manufacturers - Specialty & Generic
Canadian filerHQ Moncton, NBCIK 0001620737Reports USD
#1 of 1,418 Healthcare companies by revenue
EA Score
——FH —DQ —GM —SS 62
v0.1 · 5/100 weight · pillars only
↑ workforce scale, balance-sheet leverage · ↓ filing timeliness, Piotroski F
Methodology →Revenue TTM
$198.4M
Rev growth YoY (TTM)
+42.7%
Net income (FY)
-$33.4M
Employees
1,139
as of 2026-09-15
Market cap
$151.3M
as of 2026-09-15
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Net income-$33.4M-45.4M CAD2024
Total assets$302.1M407.9M CAD2024
Liabilities$75.5M101.9M CAD2024
Revenue by segment
Filed disclosures · FY2025
By product
International Business To Business69%
Wholesale To Licensed Producers Revenue24%
Direct To Patient Medical Revenue6%
Other Revenue0%
By geography
Not disclosed.
The read
What is Organigram Global Inc.’s financial profile?
Organigram Global Inc. earned -$33.4M in FY2024 net income.
Peers · Healthcare
Canton Strategic Holdings Inc——Conexeu Sciences Inc.——Immunic, Inc.——Tenaya Therapeutics, Inc.——Biomea Fusion, Inc.——enGene Holdings Inc.——Key facts
CEOJames Yamanaka
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersMoncton, NB
ExchangeNASDAQ: OGI
Employees1,139
IPO date2019-05-21
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.